Key Highlights
- USD 16.00 per share is the price set on October 14, 2026 by Iambic Therapeutics (NASDAQ:IAM), the midpoint of a USD 15 to 17 range. It sold 9,375,000 shares for USD 150.0 million, before an option for 1,406,250 more shares, per the prospectus.
- USD 20.65 to 21.39 is the range of latest quotes in published market data for Iambic Therapeutics (NASDAQ:IAM). That is 29.1% to 33.7% above the offer price (own arithmetic on two published numbers), after a first-day range of USD 19.31 to 22.00.
- USD 207.9 million of cash and equivalents was held at June 30, 2026, per the prospectus dated October 14. Net loss was USD 77.3 million in 2025 and USD 50.1 million in the first half of 2026.
- 47,400,796 shares are outstanding after the offering, or 48,807,046 if the option is fully exercised. At the USD 16.00 offer price that is USD 758.4 million, and at USD 20.65 it is USD 978.8 million, both own arithmetic.
Pricing and Early Trading
The offer priced at the midpoint of its range and was not upsized, per the prospectus filed October 14, 2026 for a Nasdaq Global Select Market listing. J.P. Morgan, Jefferies, BofA Securities and Citigroup led the deal. ARK Investment Management and Duquesne Family Office reportedly signalled interest in 40% of the shares, USD 60 million. Trading opened at USD 19.31, 20.7% above the offer, and reached USD 22.00. A 13.11% move to USD 21.39 in published market data implies a USD 18.91 reference price (own arithmetic), which does not tie to the offer; the session is not confirmed.
Pipeline and Cash Runway
Iambic says its AI-enabled platform designs small-molecule cancer drugs. Lead program IAM1363 is an oral HER2 inhibitor in a Phase 1/1b trial, and the pipeline includes IAM217, a KIF18A inhibitor, and IAM-C1, a CDK2/4 candidate. Nvidia (NASDAQ:NVDA) is a backer, and partnerships exist with AbbVie and Takeda. Proceeds fund IAM1363 through Phase 1 and into Phase 2 and Phase 3. Gross proceeds plus June 30 cash total USD 357.9 million; at the first-half net loss rate of USD 8.35 million a month, that covers 42.9 months (own arithmetic, before fees, net loss as proxy for cash burn).
Risks and Monitoring Points
IAM1363 is early-stage, and the AI design thesis must still translate into patient data. Annual losses are large, and a stock that opened 20.7% above its offer price can reverse when existing holders sell after lock-up periods end, with lock-up length undisclosed. The underwriters' 30-day option may add 1,406,250 shares, a 3.0% increase in the share count (own arithmetic). Monitor analyst initiations after the quiet period, any HER2 data update, the option exercise and the first quarterly report as a public company.
Where Things Stand
It can hold part of its gains, but the evidence is early. Iambic Therapeutics (NASDAQ:IAM) priced at the USD 16.00 midpoint without upsizing, and quotes of USD 20.65 to 21.39 sit 29.1% to 33.7% higher, though providers differ. Cash of USD 207.9 million at June 30, 2026, plus USD 150.0 million of gross proceeds, funds the program, while a USD 50.1 million first-half loss shows the burn. A valuation of USD 978.8 million at USD 20.65 leaves little room for trial disappointment. The next catalysts are analyst initiations, the underwriters' option and HER2 trial updates.






Please wait processing your request...